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Although iron overload is clinically signiﬁcant, only limited data have been published on iron overload in haematological
diseases. We investigated cardiac and liver iron accumulation by magnetic resonance imaging (MRI) in a cohort of 87 subjects
who did not receive chelation, including 59 haematological patients. M-HIC (MRI-based hepatic iron concentration, normal
values o36mmol/g) is a non-invasive, liver biopsy-calibrated method to analyse iron concentration. This method, calibrated to
R2 (transverse relaxation rate), was used as a reference standard (M-HIC(R2)). Transfusions and ferritin were evaluated. Mean
M-HIC(R2) and cardiac R* of all patients were 142mmol/g (95% CI, 114--170) and 36.41/s (95% CI, 34.2--38.5), respectively.
M-HIC(R2) was higher in haematological patients than in patients with chronic liver disease or normal controls (Po0.001).
Clearly elevated cardiac R2* was found in two myelodysplastic syndrome (MDS) patients with severe liver iron overload. A poor
correlation was found between liver and cardiac iron (n¼82, r¼0.322, P¼0.003), in contrast to a stronger correlation in MDS
(n¼7, r¼0.905, P¼0.005). In addition to transfusions, MDS seemed to be an independent factor in iron accumulation. In
conclusion, the risk for cardiac iron overload in haematological diseases other than MDS is very low, despite the frequently
found liver iron overload.
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INTRODUCTION
While cardiac complications secondary to transfusional iron overload
might be clinically signiﬁcant in several haematological diseases,
1
the impact of iron overload has been best characterised in
thalassaemia. Accumulation of cardiac iron has been the leading
cause of mortality in thalassaemia major.
2 In myelodysplastic
syndrome (MDS) only limited data of myocardial iron deposition
have been published,
3 but an adverse relationship between serum
ferritin levels and overall survival has been reported.
4,5 Based on
these results, transfusion need has been proposed to be included in
the new adverse prognostic factors in WHO classiﬁcation-based
prognostic scoring system.
6 In addition, iron accumulation has been
found in chronic liver disease and viral hepatitis with an association
of increased risk for severe infections.
7
There is a clinical need for a quantitative, safe and non-invasive
tool for iron measurement in speciﬁc tissues, in order to prevent
toxic sequels of iron accumulation.
8 As liver iron concentration
measurement from biopsies is invasive and serum ferritin is
nonspeciﬁc,
9,10 magnetic resonance imaging (MRI) has been used
increasingly to provide reliable, quantitative iron concentration
measurement.
8 Recent technical and methodological develop-
ments have offered validated and feasible methods, based on
proton transverse relaxation time (T2 and T2*) and its reciprocal
relaxation rate (R2 and R2*), to assess iron concentration in
liver
11- -15 and in myocardium.
16- -18 The liver R2 shows respective
sensitivity and speciﬁcity of 0.85--0.94 and 0.92--1.00 to predict
liver iron concentration at different thresholds,
12 and cardiac T2*
shows good interstudy reproducibility (coefﬁcient of variation) of
2.3--9.3%,
17,18 and consistently good interscanner
19 and intercen-
ter
20,21 reproducibility. T2* correlates inversely with iron concen-
tration, while R2* (1/T2*) correlates directly,
3,11,14,18 and cardiac
R2* values X501/s have been found to predict ventricular
dysfunction.
3,16 A speciﬁc signal intensity method M-HIC (MRI-
based hepatic iron concentration, mmol/g dry liver weight) was
calibrated to liver biopsies (3--375mmol/g) of 174 patients as an
accurate, directly proportional method for liver iron concentration
measurement. There was a mean difference of 0.8mmol/g (95% CI,
 6.3 to 7.9) between this method and the biochemical analysis.
15
The interstudy variation of MRI techniques have been found to be
comparable with the variation of liver biopsy.
11,12
Cardiac iron deposition has been a matter of debate in MDS.
Less is known about cardiac involvement in other transfusion-
dependent haematological malignancies.
3,4 A correlation between
cardiac and liver iron deposition has been investigated mainly in
chelated patients with thalassaemia. In these studies, no correla-
tion
3,16,22 but a potential causal relationship in longitudinal
analysis was found.
23 Other smaller studies in MDS
24,25 might
have been biased by iron chelation, which alters the relationship
between liver and cardiac iron, depending on the chelator
regimens.
3,26,27 Furthermore, chelation has been found to change
the R2 calibration curves.
28 Interestingly, two studies in non-
chelated patients with MDS proposed that cardiac iron excess
might occur only in the patients with the most severe liver iron
overload.
29,30
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www.nature.com/bcjThe aim of this study was to investigate the relationship and
frequency of cardiac and liver iron accumulation by MRI in a
cohort of non-chelated patients with MDS, other haematological
malignancies and chronic liver disease. Furthermore, we evaluated
the number of transfused red blood cells (RBC) and plasma ferritin
as iron indicators. Liver R2,
11,12 calibrated to M-HIC,
14,15 was used
as the reference standard (M-HIC(R2)).
PATIENTS AND METHODS
Patients and controls
Patients with clinically suspected iron overload were recruited by
specialists at the Department of Medicine in Turku University Hospital. A
total of 87 subjects, including 75 patients and 12 healthy volunteers, were
recruited in the study (Table 1). Inclusion criterion for patients, recruited
by haematologists, was a clinically suspected iron overload due to a
haematological disease with transfusion need. Inclusion criteria for
patients with chronic liver disease, recruited by hepatologists, were
decreased liver function and elevated serum ferritin levels. Exclusion
criteria were iron chelation therapy and age o18 years. One phleboto-
mised patient was excluded from the correlations between RBC and iron
load. The respective mean ages (±s.d.) of haematological patients,
patients with chronic liver disease and healthy volunteers were 49.4 years
(±13.8), 51.9 years (±11.5) and 39.4 years (±15.3) (P¼0.044). Detailed
characteristics of disease duration and transfusion dependency are
presented in Table 2. All subjects were examined by MRI between May
2007 and March 2010. This prospective, single-centre study was conducted
according to the Declaration of Helsinki guidelines. Written informed
consent was obtained from all subjects. The study protocol was approved
by the local Ethics Committee of the Hospital District of Southwest Finland.
Magnetic resonance imaging
The MRI of cardiac T2* was performed on a 1.5 T scanner (Siemens
Magnetom Avanto) and liver R2 on two 1.5 T scanners (Siemens
Magnetom Avanto and Siemens Magnetom Symphony, Siemens Medical
Solutions, Erlangen, Germany) with the combination of body-matrix and
spine-matrix surface coils. Liver imaging was obtained in 75 patients and
cardiac imaging in 73 patients. One patient with MDS and one with chronic
hepatopathy declined cardiac MRI. Liver and cardiac imaging was obtained
from 12 normal controls. Three liver R2 values from the normal controls
were missing owing to incalculable low values. The mean interval between
liver and cardiac imaging was 0.25 days (range 0- -8 days). Patients were
instructed to fast 4h before the MR examination.
Table 2. Disease duration (months), transfusion characteristics (months, units), hepatic iron (M-HIC(R2), lmol/g), cardiac iron (R2*, 1/s) and plasma
ferritin (mg/l) in haematological patients
All
haematological
patients
Acute lymphatic
leukaemia
Acute myeloid
leukaemia Aplastic anemia Lymphoma MDS Myeloﬁbrosis
P-
value
Disease duration 39.1 (26.7- -51.6) 14.3 (5.7- -22.8) 29.3 (10.2- -48.5) 66.0 ( 54.4- -186) 32.4 (12.5- -52.3) 36.0 (13.4- -58.6) 90.0 (27.8- -152) 0.045*
Transfusion
dependence
duration
12.3 (7.4- -17.2) 6.3 ( 1.2- -13.7) 9.3 (3.7- -14.8) 32.3 ( 30.8- -95.4) 5.1 ( 1.2- -11.4) 19.9 (6.7- -33.1) 13.1 (1.9- -24.3) 0.117
RBC units 34 (25- -43) 23 (2.7- -43) 42 (2.7- -43) 51 ( 3.6- -106) 11 ( 6.9- -30) 40 (23- -57) 41 ( 13- -95) 0.298
Transfusion dependency at MRI, patients, n (%)
Dependent 28 (47) 1 (14) 8 (38) 3 (60) 2 (33) 7 (88) 5 (83)
Non-dependent 31 (53) 6 (86) 13 (62) 2 (40) 4 (67) 1 (13) 1 (17)
Hepatic iron 162 (129- -196) 136 (69- -202) 177 (131- -223) 232 ( 14- -478) 59 (20- -97) 254 (136- -373) 159 (0.041- -318) 0.060
Cardiac iron 37 (34- -39) 33 (24- -42) 33 (30- -37) 42 (37- -48) 34 (26- -42) 46 (27- -65) 37 (30- -43) 0.062
Ferritin 2059 (1620- -2497) 1972 (447- -3498) 2095 (1316- -2874) 1990 (1106- -2875) 1097 ( 187- -2381) 3078 (1237- -4918) 1873 (154- -3593) 0.416
Abbreviations: CI, conﬁdence interval; M-HIC, MRI-based hepatic iron concentration; MRI, magnetic resonance imaging; RBC, red blood cells. The mean values
(95% CI) are presented. P-value was analysed as variation among the mean values of the subgroups with statistically signiﬁcant difference marked with
an asterisk*.
Table 1. Clinical characteristics of all patients
Number of patients 75
Gender, n (%)
Male 43 (57)
Female 32 (43)
Age
Mean (±s.d.) 50 (13)
Median (range) 51 (20- -82)
Diagnosis, n (%)
Haematological diseases
Acute myeloid leukaemia 21 (28)
Acute lymphatic leukaemia 7 (9.3)
Aplastic anemia 5 (6.7)
Lymphoma 6 (8.0)
Myelodysplastic syndrome 8 (11)
Myeloﬁbrosis 6 (8.0)
Other 7 (9.3)
Multiple myeloma (2)
Chronic lymphocytic leukaemia (2)
Chronic myeloid leukaemia (1)
Chronic prolymphocytic leukaemia (1)
Thalassaemia intermedia (1)
Chronic liver disease 15 (20)
Hereditary haemochromatosis (4)
Hepatopathy of unknown aetiology (6)
Steatohepatitis with hemosiderosis (3)
Other (2)
Hepatic iron concentration M-HIC(R2), mmol/g
a
Mean (95% CI) 142 (114- -170)
Median (range) 111 (5--546)
X36mmol/g, n (%) 58 (77)
o36mmol/g, n (%) 17 (23)
Cardiac iron R2*, 1/s
b
Mean (95% CI) 36.3 (34.2- -38.5)
Median (range) 36.1 (20.2- -84.6)
X501/s, n (%) 3 (4)
o501/s, n (%) 70 (96)
Abbreviations: CI, conﬁdence interval; M-HIC, magnetic resonance
imaging-based hepatic iron concentration.
aNormal values of M-HIC
(R2)o36mmol/g liver dry weight.
15 bNormal values of cardiac R2*o501/s
(i.e., T2*420ms).
16
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We used a validated T2* method ﬁrst introduced by Andersson et al.
16
ECG-gated breath-hold spoiled gradient recalled echo sequence
(2D FLASH) was applied at different echo times (TE 3, 5, 6.5, 8, 10, 12,
14, 17, 20, 23, 26 and 29ms) with the following parameters: repetition time
500ms, ﬂip angle 201, slice thickness 10mm, matrix size 128 256, ﬁeld of
view 350mm, seven phase encoding steps per cardiac cycle and time of
acquisition 15- -25s. In all, 47 subjects were scanned with TE of 3- -29ms and
40 subjects were scanned with TE of 5- -29ms. Minor differences in TE
values had been tested for consistency in two studies.
20,21 A single short-
axis mid-ventricular slice was acquired with constant imaging parameters
for each subject. A black-blood preparation pulse
31,32 was applied to
reduce artefacts in 79 subjects.
A region of interest of 1.0--1.3cm
2 was chosen for the signal intensity
measurement from the left ventricular septum.
18 All images were evaluated
by an experienced reader and selected to avoid movement artefacts. A
mono-exponential ﬁtting was used in the cardiac T2*(1/R2*) measurement
analysis.
31,32 R2* is directly proportional to iron concentration, and was
chosen as a primary cardiac iron indicator.
14 Cardiac iron overload was
deﬁned as R2*X501/s (corresponding T2*p20ms), which was used as a
cutoff point for normal and pathologically elevated cardiac iron.
16
Liver imaging and analysis
We used a T2 multi-echo spin-echo imaging sequence with fat suppression
for liver iron assessment at 11 different TE times (TE 7.2- -86.4ms, 7.2ms
interval) with the following parameters: repetition time 2000ms, ﬂip angle
1801, slice thickness 10mm, matrix size 192 256, ﬁeld of view 400mm
and time of acquisition 4.50min. Freehand region of interest was chosen
for signal intensity measurement from the right part of the right liver lobe
in segments 6 and 7 by an experienced reader avoiding vessels and
possible artefacts. A mono-exponential ﬁtting with an offset constant C
was used to deﬁne values of T2 and the reciprocal, R2(1/T2).
11
Calibration between liver R2 and M-HIC
The R2 was calibrated to a previously in vivo and in vitro validated and
biopsy-calibrated M-HIC (mmol/g liver dry weight).
14,15 As a result
(Supplementary Figure 1), we were able to use M-HIC(R2) (mmol/g liver
dry weight) as a reference standard and maintain the wide quantitative
range of R2.
11,12 The calibration is demonstrated in Supplementary
Information.
Transfusion history
The number of transfused RBC units for haematological patients was
collected via a transfusion database Trace Line (MAK-SYSTEM, Paris,
France), and patient reviews. The data were collected from 1996, when the
database was founded. Transfusion dependency duration, transfusion
dependency at the time of MRI and RBC units received at the dependency
period were evaluated. In addition, four variables were analysed to
evaluate the inﬂuence of these variables on transfusional iron accumula-
tion in the liver. These were: total cumulative number of RBC units received
(RBC); number of high-dose transfusion sessions (HDS); number of high-
dose RBC units received (HDU); and MDS. The HDS was deﬁned as the
number of transfusion sessions in which at least four RBC units were
transfused. The HDU was deﬁned as the number of cumulative RBC units of
more than two transfused in a single session. The RBC, HDS and HDU were
evaluated as quantitative variables, and MDS as a qualitative variable.
These variables were chosen based on an empiric evaluation of the whole
transfusion data in order to investigate if a high dose of RBC units received
in one session or MDS itself had an impact on iron accumulation in
the liver.
Ferritin, CRP and ALT
Plasma concentration of ferritin (mg/l) was measured electrochemically
(MEIA), C-reactive protein (CRP, mg/l) with immunoturbidimetric assay and
alanine transaminase (ALT, U/l) according to IFCC recommendation on
Roche Modular PPEE analyzer (Roche Diagnostics GmbH, Mannheim,
Germany). The median interval between blood tests and MRI was 18 days
(95% CI, 18.4- -30.0; range 0- -126 days).
Statistical analysis
Statistical tests were performed using GraphPad Prism ver. 5, Instat ver.
3.06 (GraphPad Software, Inc., San Diego, CA, USA) and SAS/STAT ver. 9.2 of
the SAS System for Windows (SAS Institute Inc., Cary, NC, USA).
The correlations were obtained using Pearson correlation and scatter
plots with least square measures linear regression analysis. Two-tailed t-
test and one-way ANOVA with Tukey- -Kramer multiple comparisons
posttest was used between the groups. The hepatic iron concentration
of haematological patients was analysed using univariate and backward
linear regression analysis with RBC, HDS, HDU and MDS (exclusion criteria,
Po0.10), the normality of residuals was tested with Shapiro- -Wilks test, and
collinearity diagnostics were performed. A receiver--operator characteristic
curve was applied to search the optimal thresholds, with speciﬁcity (%),
sensitivity (%), positive predictive value (PPV, %) and negative predictive
value (NPV, %), and to test accuracy (area under curve (AUC)) of iron
indicators. Statistical signiﬁcance was deﬁned as Po0.05.
RESULTS
Cardiac and liver iron overload
Liver iron overload (M-HIC(R2)X36mmol/g) was frequent, com-
pared with cardiac iron overload (R2*X501/s) (Table 1). Liver iron
overload was found in the majority of haematological patients
(49/59, 83%) and in patients with chronic liver disease (8/15, 53%).
Only three haematological patients showed cardiac iron overload.
None of the patients with chronic liver disease had cardiac iron
overload and none of the normal controls had either cardiac or
liver iron overload.
The mean liver M-HIC(R2) was higher in haematological patients
than in patients with chronic liver disease or normal controls, with
respective mean values of 162mmol/g (95% CI, 129--196), 66mmol/
g (95% CI, 33--100) and 15mmol/g (95% CI, 7--24) (Po0.001).
Haematological patients showed higher plasma ferritin than
patients with chronic liver disease with respective mean values
of 2060mg/l (95% CI, 1620--2500) and 943mg/l (95% CI, 405--1480)
(P¼0.020). Cardiac R2* did not differ signiﬁcantly between
haematological patients, patients with chronic liver disease and
normal controls with respective mean values of 371/s (95% CI,
34--39), 361/s (95% CI, 33--39) and 341/s (95% CI, 31--37)
(P¼0.714).
Clinical characteristics and iron overload in haematological
patients
In haematological patients, clinical characteristics and hepatic and
cardiac iron load are presented in Table 2. Only disease duration
reached statistical signiﬁcance among the mean differences of the
subgroups and in the multiple comparison test between acute
lymphatic leukaemia (ALL) and myeloﬁbrosis (Po0.05). Disease
duration correlated weakly with liver iron (r¼0.290, P¼0.026),
and did not correlate with cardiac iron (r¼0.130, P¼0.368).
Transfusion dependency duration correlated moderately with total
RBC (r¼0.5621, Po0.001) and liver iron (r¼0.6383, Po0.001), but
not with cardiac iron (r¼0.2203, P¼0.0965). Patients with MDS
showed the highest mean cardiac and liver iron levels. Clearly
elevated cardiac R2* was found in only two patients with MDS
(R2*¼85 and 591/s). A 20-year-old patient with precursor-B-cell
ALL showed a borderline cardiac iron level (R2*¼521/s). His
disease history was not unusual, with respective disease and
transfusion durations of 831 and 81 days. The patient had a normal
echocardiography, tested negative for haemochromatosis and had
no other comorbidities. Examples of iron accumulation in different
patients are illustrated by cardiac MR images (Figures 1a--c).
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In MDS, there was a highly signiﬁcant correlation (Figure 2a)
between hepatic and cardiac iron overload (n¼7, r¼0.905,
P¼0.005). In the other diagnostic subgroups of aplastic anemia,
acute lymphatic leukaemia, acute myeloid leukaemia, chronic
leukaemia, lymphomas and chronic liver disease, no statistically
signiﬁcant correlation was found between hepatic and cardiac
iron (P40.43). The only exception was the group of patients with
myeloﬁbrosis, where the correlation reached statistical signiﬁ-
cance (n¼6, r¼0.863, P¼0.027). In all subjects, the correlation
(Figure 2b) was weak but signiﬁcant (n¼82, r¼0.322, P¼0.003).
The effect of transfusion indexes and MDS on liver iron
In haematological patients, we used a backward regression
analysis to evaluate the inﬂuence of the transfusion indexes
(RBC, HDS and HDU) and MDS on hepatic iron accumulation. The
RBC (Po0.001) and MDS (P¼0.002) were the only explaining
variables left in the ﬁnal model. The HDT or HDU had no impact on
the hepatic iron accumulation from transfusions (P40.32). This
model with a linear ﬁt suggested that MDS is an independent
variable that increases the transfusional liver iron overload with an
average of 79mmol/g compared with non-MDS patients.
RBC and ferritin as iron indicators in haematological patients
Hepatic iron concentration correlated signiﬁcantly with both RBC
and plasma ferritin (Figures 3a and b). The correlation with RBC
was higher (n¼58, r¼0.840, Po0.001) than with ferritin (n¼55.
r¼0.676, Po0.001). In all patients, the correlation with ferritin
remained signiﬁcant (r¼0.713, Po0.001). The RBC was found to
be more accurate than ferritin in predicting liver iron overload, as
shown in receiver--operator characteristic analysis. The respective
optimal threshold values for RBC and ferritin to predict iron
overload were 13 RBC units (AUC¼0.940, 100% speciﬁcity, 87.5%
sensitivity, 100% PPV and 62.5% NPV) and 1019mg/l (AUC¼0.843,
80% speciﬁcity, 81% sensitivity, 93% PPV and 55% NPV). Cardiac
iron did not correlate with RBC (n¼57, r¼0.100, P¼0.457), and
the correlation with ferritin was weak (n¼54, r¼0.366, P¼0.007).
ALT, CRP and age
Mean ALT was at the same level in patients with haematological
and chronic liver disease (P¼0.959); the respective mean values
were 65U/l (95% CI, 46--84) and 66U/l (95% CI, 11--122). The
respective mean CRP of patients with haematological and liver
disease were 7.1mg/l (95% CI, 4.6--9.6) and 61.5mg/l (95% CI,
78.4--201.4) (P¼0.004). CRP did not correlate with ferritin (n¼54,
r¼ 0.041, P¼0.768). ALT, CRP or patient age did not correlate
with hepatic iron concentration (P¼0.192, 0.700 and 0.088,
respectively). Ages correlated poorly with cardiac iron (r¼0.314,
P¼0.007).
DISCUSSION
Liver and cardiac iron overload in the whole study cohort
In our study, cardiac iron overload was a rarity, despite the high
frequency of liver iron overload, which was a cardinal feature in
RBC transfused haematological malignancies. In general, iron load
in haematological malignancies was higher than in chronic liver
Figure 1. Cardiac short-axis left ventricular MR images of three patients with similar parameters (TE¼8ms). The images illustrate the different
degrees of hepatic and cardiac iron accumulation, which is seen as a signal drop. A signal intensity of myocardium was measured with
constant region of interest (oval line) from MR images in each patient. Subphrenic liver, marked with an asterisk, is situated at the lower part
of the image. (a) A patient with ALL; normal level of cardiac R2* (301/s) with only slightly elevated hepatic iron concentration (40mmol/g).
There is no visible signal drop found in the liver or the heart. (b) A patient with AML; cardiac R2* (371/s) was normal, although there
was heavy hepatic iron overload (380mmol/g). The liver signal dropped owing to the severe iron overload, giving more contrast to the
normal cardiac tissue. (c) A patient with MDS; pathologically low R2* (851/s), indicating cardiac iron overload with simultaneous severe
hepatic iron overload (488mmol/g). The ﬁgure shows the signal drop of both cardiac and hepatic tissue due to excess iron.
Figure 2. A correlation between cardiac R2* and hepatic iron concentration. (a) In MDS, the cardiac iron (R2*) increases as hepatic iron
concentrations increase, showing a strong dependence. Two of the MDS patients had the highest R2* values among the entire cohort.
(b) All subjects (n¼82) showed a weak dependence between cardiac and hepatic iron concentrations.
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iron accumulation in all patients, which is in agreement with other
cross-sectional studies, mostly done in thalassaemia.
16,22,33 In our
cohort, this reﬂected the low frequency of cardiac iron overload.
We can conclude that in haematological patients other than MDS,
the risk of elevated cardiac iron is very low, which is a novel
ﬁnding in adults.
33
Liver and cardiac iron overload in haematological patients
We found liver iron overload in a large variety of haematological
malignancies due to transfused units of RBC, which correlated
strongly with liver iron. In contrast, RBC showed no correlation
with the infrequently found cardiac iron load. There were no
distinct differences found in the mean transfusion characteristics
among the diagnostic subgroups (Table 2). Only distinct feature
was the large proportion of transfusion-dependent patients in
both MDS and myeloﬁbrosis at the time of MRI, which was to be
expected. The correlation between transfusion dependency
duration and liver iron was moderate. Apparently, this can be
explained by the fact that dependency duration reﬂected the
number of transfused RBC. The frequently found hepatic iron
overload and the level of iron concentration were in agreement
with the results of a previous study with a similar cohort as ours.
34
To our knowledge, cardiac R2* has not been studied earlier in a
variety of adult haematological malignancies, but our R2* level for
normal controls was generally consistent with the results of
previous studies.
16,17,19 In our cohort, clearly elevated cardiac iron
was found in only two MDS patients. This principally agrees with
earlier results in MDS, although there has been some incon-
sistency in the results.
3,4 Jensen et al.
29 found elevated cardiac iron
in 9/12 non-chelated patients with MDS, using a different method
for cardiac iron measurement than we used. Di Tucci et al.
30 found
3/22, Chacko et al.
25 1/11 and Konen et al.
24 1/10 patients with
cardiac iron overload measured with the T2* method similar
to ours.
Liver and cardiac iron overload in patients with MDS
In patients with MDS, both cardiac and liver iron overload were
more pronounced than in any other subgroups. Our results
suggest that iron load was increased owing to both RBC
transfusions and MDS itself. The transfusion characteristics, high-
volume transfusions (HDS or HDU) or patient age could not
explain this result. These ﬁndings in MDS can be explained with
ineffective erythropoiesis, which may lead to already increased
iron overload before transfusions begin. Apparently, the high
erythropoietic activity can lead to downregulation of hepcidin and
paradoxically increased iron absorption, even when body iron
levels are already elevated.
4 Especially MDS patients with isolated
erythroid dysplasia and low risk of leukaemic evolution are more
likely to develop parenchymal iron overload and organ damage.
35
In our study, both of the MDS patients with severe liver iron
overload (4269mmol/g)
12 also had cardiac iron overload. Inter-
estingly, this threshold for elevated cardiac iron was not found in
any other haematological malignancies, despite of the severe iron
overload. This result for MDS agrees with a previously detected
threshold of 269mmol/g for greatly increased risk for cardiac
disease and early death.
12 Similarly, Jensen et al.
29 and Di Tucci
et al.
30 found a critical level of liver iron concentration in non-
chelated MDS patients, after which cardiac iron overload occurs,
although they used different methodologies than we used and
failed to demonstrate correlations. Thus, our results together with
the earlier ﬁndings suggest that there is a critical level of liver iron
concentration for predicting cardiac iron overload in MDS. The
correlation we found, between hepatic and cardiac iron in MDS
and in myeloﬁbrosis, was stronger than previously reported in
patients with chelation treatment.
24,25 In addition, there have
been suggestions of a longitudinal causal relationship between
liver and cardiac iron accumulation in chelated patients with
thalassaemia.
23 Our results do not discount this possibility, but a
causal relationship may be more apparent in chelated non-MDS
patients. By excluding the chelated patients, we were able to
explore the natural course of the iron accumulation at a selected
cross-sectional time point and observe good correlation between
liver and cardiac iron overload in patients with MDS and
myeloﬁbrosis.
Clinical relevance of liver iron measurement by quantitative MRI
and iron indicators
The quantitative range of the M-HIC(R2) in this study (5--546mmol/
g) covered the clinically signiﬁcant liver iron concentration range
from normal values beyond severe liver iron overload. A total of
71mmol/g is considered a threshold for screening haemochroma-
tosis, in which progressive iron accumulation potentially generates
ﬁbrosis.
13 In transfusional iron overload, values from 57 to
125mmol/g are suggested for the limits of optimal chelation
therapy, after which iron-induced complications increases.
12 The
calibration curve of our method between the R2 (Wood et al.
11
and St Pierre et al.
12) and M-HIC
14 (Supplementary Figure 1)
enabled this wide range of concentrations, based on R2 analysis.
The iron indicators of both RBC and ferritin were able to
estimate M-HIC(R2), but the accuracy of RBC was higher in our
cohort. Although the dependence of both of these indicators did
not reach the level of quantitative MRI methods described in the
Supplementary Information, we did ﬁnd respective thresholds for
RBC and ferritin to detect liver iron overload (13 RBC units and
1019mg/l) with high PPV. One previous study in patients after
allogeneic stem cell transplantation by Rose et al.
34 also found
Figure 3. In haematological patients, both transfusion load (RBC) and ferritin can be used to estimate iron concentrations (HICest). The number
of RBC units was more accurate, with better correlations in estimating liver iron concentration with linear ﬁt. (a) The correlation between
hepatic iron concentration and RBC (range 0--144) is demonstrated with the equation HICest(transfusion)¼4.6RBCþ2.1. (b) The correlation
between hepatic iron concentration and ferritin is demonstrated with the equation HICest(ferritin)¼0.12ferritin 77.
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our cohort were collected at the time when CRP level was low,
so ferritin was not compromised by the effects of allogeneic
transplantation or infection. Indeed, infectious or inﬂammatory
conditions were found to weaken the correlation between ferritin
and liver iron in a cohort resembling ours.
10 In clinical practice, we
suggest that RBC is a more reliable iron indicator in haematolo-
gical patients, if patients with chelation treatment or phlebotomy
are excluded. However, some precautions should be taken
regarding MDS, where transfusions may be responsible for only
a part of the iron load.
4 Thus, there remains an indication for
ferritin measurement as well.
Limitations of the study
We were able to show an increased risk of MDS patients for iron
overload with a relatively small cohort. The variation in the
number of patients in the diagnostic subgroups may have had
some inﬂuence on the results, for example, in the transfusion
characteristics of the haematological subgroups. Thus, larger
studies in patients with MDS are still needed to conﬁrm our
ﬁndings. Moreover, transfusion history was collected from the year
the database was founded. The vast majority of the patients were
diagnosed after this, and there should be no major bias in RBC
collection, which is seen in the strong correlation. Nevertheless,
this limitation together with the MDS feature of ‘intrinsic’ iron
accumulation might had some inﬂuence in the relatively low
cutoff value of 13 RBC units to predict liver iron overload. Third,
the control group was B10 years younger than the patients.
However, this should not have inﬂuenced the results, because in
an earlier study in our unit a similar group of volunteers did not
show any correlation between ages and liver iron concentration
measured by T2 (1/R2).
36 Finally, no direct invasive measurements
of tissue concentrations were available. However, the MRI
methods we used are justiﬁed as widely validated, non-invasive
indicators for iron concentration.
11,12,21 In cardiac imaging, we
used black-blood preparation pulse in the majority of subjects as
this technique has been found to be comparable to the more
conventional technique used in minor extent in this study.
31
Conclusion
In conclusion, the risk for cardiac iron overload in patients with
haematological disease other than MDS is very low, despite the
frequent ﬁnding of liver iron overload. Patients with MDS were
more susceptible than other patients to both cardiac and hepatic
iron overload. Cardiac and hepatic iron correlated signiﬁcantly in
patients with MDS and myeloﬁbrosis. A larger study of non-
chelated patients would be needed to explore these results
further. Both transfused RBC units and ferritin have certain
limitations, but can be used as semi-quantitative indicators of
liver iron.
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